Japan Tobacco applies to sell anti-HIV tablet in Japan
TOKYO Dec 6 (Reuters) - Japan Tobacco Inc said on Thursday it has applied to sell an anti-HIV drug treatment in Japan.
If approved by the Health Ministry, it would be the only once-daily single-tablet regimen for HIV infection in Japan, it said.
The drug contains JT's compound elvitegravir, which is used in Gilead Sciences Inc's Stribild regimen, approved by the U.S. Food and Drug Administration in August 2012.
JT licensed elvitegravir to Gilead in 2005, giving Gilead exclusive rights to develop and commercialise the drug worldwide outside Japan. (Reporting by Mayumi Negishi; Editing by Michael Watson)
- Putin dissolves state news agency, tightens grip on Russia media
- North Korea says Kim's powerful uncle dismissed for 'criminal acts'
- Thai PM calls snap election, protesters want power now |
- Record cold, ice grip U.S.; more snow to blanket East
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'